Beyond NK activation, the antibody promoted caspase-3-dependent apoptosis of ROR1+ tumor cells without inducing significant, irreversible antigen downregulation, suggesting a reduced risk of resistance through target loss, a common barrier observed in many therapies. Here, CASP3 is linked to neoplasm.